001     127019
005     20240228140901.0
024 7 _ |a 10.1038/onc.2014.405
|2 doi
024 7 _ |a pmid:25531316
|2 pmid
024 7 _ |a pmc:PMC4386991
|2 pmc
024 7 _ |a 0950-9232
|2 ISSN
024 7 _ |a 1476-5594
|2 ISSN
024 7 _ |a altmetric:3009370
|2 altmetric
037 _ _ |a DKFZ-2017-03045
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Lindsey, J. C.
|b 0
245 _ _ |a Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance.
260 _ _ |a Basingstoke
|c 2015
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1508835331_20352
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The identification of key tumorigenic events in Sonic Hedgehog (SHH) subgroup medulloblastomas (MBSHH) will be essential for the development of individualized therapies and improved outcomes. However, beyond confirmation of characteristic SHH pathway mutations, recent genome-wide sequencing studies have not revealed commonly mutated genes with widespread relevance as potential therapeutic targets. We therefore examined any role for epigenetic DNA methylation events in MBSHH using a cross-species approach to candidate identification, prioritization and validation. MBSHH-associated DNA methylation events were first identified in 216 subgrouped human medulloblastomas (50 MBSHH, 28 Wnt/Wingless, 44 Group 3 and 94 Group 4) and their conservation then assessed in tumors arising from four independent murine models of Shh medulloblastoma, alongside any role in tumorigenesis using functional assessments in mouse and human models. This strategy identified widespread regional CpG hypo-methylation of VAV1, leading to its elevated expression, as a conserved aberrant epigenetic event, which characterizes the majority of MBSHH tumors in both species, and is associated with a poor outcome in MBSHH patients. Moreover, direct modulation of VAV1 in mouse and human models revealed a critical role in tumor maintenance, and its abrogation markedly reduced medulloblastoma growth. Further, Vav1 activity regulated granule neuron precursor germinal zone exit and migration initiation in an ex vivo model of early postnatal cerebellar development. These findings establish VAV1 as a critical epigenetically regulated oncogene with a key role in MBSHH maintenance, and highlight its potential as a validated therapeutic target and prognostic biomarker for the improved therapy of medulloblastoma.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Proto-Oncogene Proteins c-vav
|2 NLM Chemicals
650 _ 7 |a VAV1 protein, human
|2 NLM Chemicals
700 1 _ |a Kawauchi, D.
|0 P:(DE-He78)0ac2bd1a9fb1823a351ee4434d80808b
|b 1
|u dkfz
700 1 _ |a Schwalbe, E. C.
|b 2
700 1 _ |a Solecki, D. J.
|b 3
700 1 _ |a Selby, M. P.
|b 4
700 1 _ |a McKinnon, P. J.
|b 5
700 1 _ |a Olson, J. M.
|b 6
700 1 _ |a Hayden, J. T.
|b 7
700 1 _ |a Grundy, R. G.
|b 8
700 1 _ |a Ellison, D. W.
|b 9
700 1 _ |a Williamson, D.
|b 10
700 1 _ |a Bailey, S.
|b 11
700 1 _ |a Roussel, M. F.
|b 12
700 1 _ |a Clifford, S. C.
|b 13
773 _ _ |a 10.1038/onc.2014.405
|g Vol. 34, no. 36, p. 4746 - 4757
|0 PERI:(DE-600)2008404-3
|n 36
|p 4746 - 4757
|t Oncogene
|v 34
|y 2015
|x 1476-5594
909 C O |o oai:inrepo02.dkfz.de:127019
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)0ac2bd1a9fb1823a351ee4434d80808b
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONCOGENE : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ONCOGENE : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21